Clinical Scorecard: SALWEEN Results Show Durable PCV Treatment
At a Glance
| Category | Detail |
|---|---|
| Condition | Polypoidal Choroidal Vasculopathy (PCV) |
| Key Mechanisms | Abnormal blood vessels beneath the retina leading to vision loss. |
| Target Population | Patients aged 50 and older in Asian populations. |
| Care Setting | Ophthalmology clinics across Asia. |
Key Highlights
- Patients gained an average of 8.9 letters in best-corrected visual acuity (BCVA) after 1 year.
- Over 50% of patients extended treatment intervals to 20 weeks.
- 61% of patients showed complete regression of polypoidal lesions.
- 86% achieved lesion inactivation, reducing risks of bleeding and vision loss.
- Safety results consistent with earlier global trials.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of PCV should be confirmed through imaging techniques.
Management
- Initiate treatment with 4 loading doses of Vabysmo over 12 weeks, followed by personalized dosing.
Monitoring & Follow-up
- Regular assessment of BCVA and retinal swelling to adjust treatment intervals.
Risks
- Monitor for potential bleeding and progressive vision loss.
Patient & Prescribing Data
135 patients aged 50 and older from 9 Asian markets.
Vabysmo therapy may significantly reduce treatment burden while maintaining vision.
Clinical Best Practices
- Adopt personalized treatment plans based on patient progress.
- Consider long-acting treatment options for aging populations.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.